|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chang JS, Kuo SH, Chu PY, Shan YS, Tsai
CR, Tsai HJ and Chen LT: The epidemiology of gastric cancers in the
era of Helicobacter pylori eradication: A nationwide cancer
registry-based study in Taiwan. Cancer Epidemiol Biomarkers Prev.
28:1694–1703. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Waddell T, Verheij M, Allum W, Cunningham
D, Cervantes A and Arnold D; European Society for Medical Oncology
(ESMO); European Society of Surgical Oncology (ESSO); European
Society of Radiotherapy, Oncology (ESTRO), : Gastric cancer:
ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis,
treatment and follow-up. Ann Oncol. 24 (Suppl 6):vi57–vi63. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Japanese Gastric Cancer Association, .
Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric
Cancer. 20:1–19. 2017. View Article : Google Scholar
|
|
5
|
Wagner AD, Syn NL, Moehler M, Grothe W,
Yong WP, Tai BC, Ho J and Unverzagt S: Chemotherapy for advanced
gastric cancer. Cochrane Database Syst Rev.
8:CD0040642017.PubMed/NCBI
|
|
6
|
Park SC and Chun HJ: Chemotherapy for
advanced gastric cancer: Review and update of current practices.
Gut Liver. 7:385–393. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shirao K, Boku N, Yamada Y, Yamaguchi K,
Doi T, Goto M, Nasu J, Denda T, Hamamoto Y, Takashima A, et al:
Randomized phase III study of 5-fluorouracil continuous infusion vs
sequential methotrexate and 5-fluorouracil therapy in far advanced
gastric cancer with peritoneal metastasis (JCOG0106). Jpn J Clin
Oncol. 43:972–980. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Guimbaud R, Louvet C, Ries P, Ychou M,
Maillard E, André T, Gornet JM, Aparicio T, Nguyen S, Azzedine A,
et al: Prospective, randomized, multicenter, phase III study of
fluorouracil, leucovorin, and irinotecan versus epirubicin,
cisplatin, and capecitabine in advanced gastric adenocarcinoma: A
French intergroup (Fédération Francophone de Cancérologie
Digestive, Fédération Nationale des Centres de Lutte Contre le
Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie)
study. J Clin Oncol. 32:3520–3526. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Van Cutsem E, Boni C, Tabernero J, Massuti
B, Middleton G, Dane F, Reichardt P, Pimentel FL, Cohn A, Follana
P, et al: Docetaxel plus oxaliplatin with or without fluorouracil
or capecitabine in metastatic or locally recurrent gastric cancer:
A randomized phase II study. Ann Oncol. 26:149–156. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lu Z, Zhang X, Liu W, Liu T, Hu B, Li W,
Fan Q, Xu J, Xu N, Bai Y, et al: A multicenter, randomized trial
comparing efficacy and safety of paclitaxel/capecitabine and
cisplatin/capecitabine in advanced gastric cancer. Gastric Cancer.
21:782–791. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ryu MH, Baba E, Lee KH, Park YI, Boku N,
Hyodo I, Nam BH, Esaki T, Yoo C, Ryoo BY, et al: Comparison of two
different S-1 plus cisplatin dosing schedules as first-line
chemotherapy for metastatic and/or recurrent gastric cancer: A
multicenter, randomized phase III trial (SOS). Ann Oncol.
26:2097–2101. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yamada Y, Higuchi K, Nishikawa K, Gotoh M,
Fuse N, Sugimoto N, Nishina T, Amagai K, Chin K, Niwa Y, et al:
Phase III study comparing oxaliplatin plus S-1 with cisplatin plus
S-1 in chemotherapy-naïve patients with advanced gastric cancer.
Ann Oncol. 26:141–148. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ajani JA, Abramov M, Bondarenko I, Shparyk
Y, Gorbunova V, Hontsa A, Otchenash N, Alsina M, Lazarev S, Feliu
J, et al: A phase III trial comparing oral S-1/cisplatin and
intravenous 5-fluorouracil/cisplatin in patients with untreated
diffuse gastric cancer. Ann Oncol. 28:2142–2148. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hu HM, Tsai HJ, Ku HY, Lo SS, Shan YS,
Chang HC, Chao Y, Chen JS, Chen SC, Chiang CJ, et al: Survival
outcomes of management in metastatic gastric adenocarcinoma
patients. Sci Rep. 11:231422021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y,
Kato K, Chung HC, Chen JS, Muro K, Kang WK, et al: Nivolumab in
patients with advanced gastric or gastro-oesophageal junction
cancer refractory to, or intolerant of, at least two previous
chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised,
double-blind, placebo-controlled, phase 3 trial. Lancet.
390:2461–2471. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shitara K, Doi T, Dvorkin M, Mansoor W,
Arkenau HT, Prokharau A, Alsina M, Ghidini M, Faustino C, Gorbunova
V, et al: Trifluridine/tipiracil versus placebo in patients with
heavily pretreated metastatic gastric cancer (TAGS): A randomised,
double-blind, placebo-controlled, phase 3 trial. Lancet Oncol.
19:1437–1448. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kristensen LS, Jakobsen T, Hager H and
Kjems J: The emerging roles of circRNAs in cancer and oncology. Nat
Rev Clin Oncol. 19:188–206. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sanger HL, Klotz G, Riesner D, Gross HJ
and Kleinschmidt AK: Viroids are single-stranded covalently closed
circular RNA molecules existing as highly base-paired rod-like
structures. Proc Natl Acad Sci USA. 73:3852–3856. 1976. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jeck WR, Sorrentino JA, Wang K, Slevin MK,
Burd CE, Liu J, Marzluff WF and Sharpless NE: Circular RNAs are
abundant, conserved, and associated with ALU repeats. RNA.
19:141–157. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lu T, Cui L, Zhou Y, Zhu C, Fan D, Gong H,
Zhao Q, Zhou C, Zhao Y, Lu D, et al: Transcriptome-wide
investigation of circular RNAs in rice. RNA. 21:2076–2087. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Memczak S, Jens M, Elefsinioti A, Torti F,
Krueger J, Rybak A, Maier L, Mackowiak SD, Gregersen LH, Munschauer
M, et al: Circular RNAs are a large class of animal RNAs with
regulatory potency. Nature. 495:333–338. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rybak-Wolf A, Stottmeister C, Glažar P,
Jens M, Pino N, Giusti S, Hanan M, Behm M, Bartok O, Ashwal-Fluss
R, et al: Circular RNAs in the mammalian brain are highly abundant,
conserved, and dynamically expressed. Mol Cell. 58:870–885. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gao Y, Wang J, Zheng Y, Zhang J, Chen S
and Zhao F: Comprehensive identification of internal structure and
alternative splicing events in circular RNAs. Nat Commun.
7:120602016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang Y, Xue W, Li X, Zhang J, Chen S,
Zhang JL, Yang L and Chen LL: The biogenesis of nascent circular
RNAs. Cell Rep. 15:611–624. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Capel B, Swain A, Nicolis S, Hacker A,
Walter M, Koopman P, Goodfellow P and Lovell-Badge R: Circular
transcripts of the testis-determining gene Sry in adult mouse
testis. Cell. 73:1019–1030. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li X, Zhang JL, Lei YN, Liu XQ, Xue W,
Zhang Y, Nan F, Gao X, Zhang J, Wei J, et al: Linking circular
intronic RNA degradation and function in transcription by RNase H1.
Sci China Life Sci. 64:1795–1809. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Guo J, Agarwal V, Guo H and Bartel D:
Expanded identification and characterization of mammalian circular
RNAs. Genome Biol. 15:4092014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Thomson DW and Dinger ME: Endogenous
microRNA sponges: Evidence and controversy. Nat Rev Genet.
17:272–283. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Du WW, Yang W, Chen Y, Wu ZK, Foster FS,
Yang Z, Li X and Yang BB: Foxo3 circular RNA promotes cardiac
senescence by modulating multiple factors associated with stress
and senescence responses. Eur Heart J. 38:1402–1412.
2017.PubMed/NCBI
|
|
30
|
Holdt LM, Stahringer A, Sass K, Pichler G,
Kulak NA, Wilfert W, Kohlmaier A, Herbst A, Northoff BH, Nicolaou
A, et al: Circular non-coding RNA ANRIL modulates ribosomal RNA
maturation and atherosclerosis in humans. Nat Commun. 7:124292016.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kozak M: Inability of circular mRNA to
attach to eukaryotic ribosomes. Nature. 280:82–85. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen CY and Sarnow P: Initiation of
protein synthesis by the eukaryotic translational apparatus on
circular RNAs. Science. 268:415–417. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Abe N, Matsumoto K, Nishihara M, Nakano Y,
Shibata A, Maruyama H, Shuto S, Matsuda A, Yoshida M, Ito Y and Abe
H: Rolling circle translation of circular RNA in living human
cells. Sci Rep. 5:164352015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Legnini I, Di Timoteo G, Rossi F, Morlando
M, Briganti F, Sthandier O, Fatica A, Santini T, Andronache A, Wade
M, et al: Circ-ZNF609 Is a circular RNA that can be translated and
functions in myogenesis. Mol Cell. 66:22–37.e9. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li H, Li K, Lai W, Li X, Wang H, Yang J,
Chu S, Wang H, Kang C and Qiu Y: Comprehensive circular RNA
profiles in plasma reveals that circular RNAs can be used as novel
biomarkers for systemic lupus erythematosus. Clin Chim Acta.
480:17–25. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hansen TB, Jensen TI, Clausen BH, Bramsen
JB, Finsen B, Damgaard CK and Kjems J: Natural RNA circles function
as efficient microRNA sponges. Nature. 495:384–388. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Piwecka M, Glažar P, Hernandez-Miranda LR,
Memczak S, Wolf SA, Rybak-Wolf A, Filipchyk A, Klironomos F, Cerda
Jara CA, Fenske P, et al: Loss of a mammalian circular RNA locus
causes miRNA deregulation and affects brain function. Science.
357:eaam85262017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang X, Yang D and Wei Y: Overexpressed
CDR1as functions as an oncogene to promote the tumor progression
via miR-7 in non-small-cell lung cancer. Onco Targets Ther.
11:3979–3987. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tang W, Ji M, He G, Yang L, Niu Z, Jian M,
Wei Y, Ren L and Xu J: Silencing CDR1as inhibits colorectal cancer
progression through regulating microRNA-7. Onco Targets Ther.
10:2045–2056. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Su C, Han Y, Zhang H, Li Y, Yi L, Wang X,
Zhou S, Yu D, Song X, Xiao N, et al: CiRS-7 targeting miR-7
modulates the progression of non-small cell lung cancer in a manner
dependent on NF-κB signalling. J Cell Mol Med. 22:3097–3107. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Weng W, Wei Q, Toden S, Yoshida K,
Nagasaka T, Fujiwara T, Cai S, Qin H, Ma Y and Goel A: Circular RNA
ciRS-7-A promising prognostic biomarker and a potential therapeutic
target in colorectal cancer. Clin Cancer Res. 23:3918–3928. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Pan H, Li T, Jiang Y, Pan C, Ding Y, Huang
Z, Yu H and Kong D: Overexpression of circular RNA ciRS-7 abrogates
the tumor suppressive effect of miR-7 on gastric cancer via
PTEN/PI3K/AKT signaling pathway. J Cell Biochem. 119:440–446. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Liu L, Liu FB, Huang M, Xie K, Xie QS, Liu
CH, Shen MJ and Huang Q: Circular RNA ciRS-7 promotes the
proliferation and metastasis of pancreatic cancer by regulating
miR-7-mediated EGFR/STAT3 signaling pathway. Hepatobiliary
Pancreatic Dis Int. 18:580–586. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ye F, Gao G, Zou Y, Zheng S, Zhang L, Ou
X, Xie X and Tang H: circFBXW7 inhibits malignant progression by
sponging miR-197-3p and encoding a 185-aa protein in
triple-negative breast cancer. Mol Ther Nucleic Acids. 18:88–98.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Li Y, Wang Z, Su P, Liang Y, Li Z, Zhang
H, Song X, Han D, Wang X, Liu Y, et al: circ-EIF6 encodes
EIF6-224aa to promote TNBC progression via stabilizing MYH9 and
activating the Wnt/beta-catenin pathway. Mol Ther. 30:415–430.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wang L, Tong X, Zhou Z, Wang S, Lei Z,
Zhang T, Liu Z, Zeng Y, Li C, Zhao J, et al: Circular RNA
hsa_circ_0008305 (circPTK2) inhibits TGF-β-induced
epithelial-mesenchymal transition and metastasis by controlling
TIF1γ in non-small cell lung cancer. Mol Cancer. 17:1402018.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhang X, Wang S, Wang H, Cao J, Huang X,
Chen Z, Xu P, Sun G, Xu J, Lv J and Xu Z: Circular RNA circNRIP1
acts as a microRNA-149-5p sponge to promote gastric cancer
progression via the AKT1/mTOR pathway. Mol Cancer. 18:202019.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Peng Y, Xu Y, Zhang X, Deng S, Yuan Y, Luo
X, Hossain MT, Zhu X, Du K, Hu F, et al: A novel protein
AXIN1-295aa encoded by circAXIN1 activates the Wnt/β-catenin
signaling pathway to promote gastric cancer progression. Mol
Cancer. 20:1582021. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Dong J, Zheng Z, Zhou M, Wang Y, Chen J,
Cen J, Cao T, Yang T, Xu Y, Shu G, et al: EGCG-LYS fibrils-mediated
CircMAP2K2 silencing decreases the proliferation and metastasis
ability of gastric cancer cells in vitro and in vivo. Adv Sci
(Weinh). 10:e23040752023. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Ma L, Wang Z, Xie M, Quan Y, Zhu W, Yang
F, Zhao C, Fan Y, Fang N, Jiang H, et al: Silencing of circRACGAP1
sensitizes gastric cancer cells to apatinib via modulating
autophagy by targeting miR-3657 and ATG7. Cell Death Dis.
11:1692020. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Jie M, Wu Y, Gao M, Li X, Liu C, Ouyang Q,
Tang Q, Shan C, Lv Y, Zhang K, et al: CircMRPS35 suppresses gastric
cancer progression via recruiting KAT7 to govern histone
modification. Mol Cancer. 19:562020. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ding L, Zhao Y, Dang S, Wang Y, Li X, Yu
X, Li Z, Wei J, Liu M and Li G: Circular RNA circ-DONSON
facilitates gastric cancer growth and invasion via NURF complex
dependent activation of transcription factor SOX4. Mol Cancer.
18:452019. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Liu B, Ye B, Yang L, Zhu X, Huang G, Zhu
P, Du Y, Wu J, Qin X, Chen R, et al: Long noncoding RNA lncKdm2b is
required for ILC3 maintenance by initiation of Zfp292 expression.
Nat Immunol. 18:499–508. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Zhang JY, Du Y, Gong LP, Shao YT, Pan LJ,
Feng ZY, Pan YH, Huang JT, Wen JY, Sun LP, et al: Corrigendum to
‘ebv-circRPMS1 promotes the progression of EBV-associated gastric
carcinoma via Sam68-dependent activation of METTL3 [Cancer Letters
535 (2022) 215646]’. Cancer Lett. 545:2158242022. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Ma X, Chen H, Li L, Yang F, Wu C and Tao
K: CircGSK3B promotes RORA expression and suppresses gastric cancer
progression through the prevention of EZH2 trans-inhibition. J Exp
Clin Cancer Res. 40:3302021. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Lee JM, Kim IS, Kim H, Lee JS, Kim K, Yim
HY, Jeong J, Kim JH, Kim JY, Lee H, et al: RORalpha attenuates
Wnt/beta-catenin signaling by PKCalpha-dependent phosphorylation in
colon cancer. Mol Cell. 37:183–195. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Yang F, Hu A, Li D, Wang J, Guo Y, Liu Y,
Li H, Chen Y, Wang X, Huang K, et al: Correction: Circ-HuR
suppresses HuR expression and gastric cancer progression by
inhibiting CNBP transactivation. Mol Cancer. 22:1552023. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Kotta-Loizou I, Giaginis C and Theocharis
S: Clinical significance of HuR expression in human malignancy. Med
Oncol. 31:1612014. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Mukherjee N, Corcoran DL, Nusbaum JD, Reid
DW, Georgiev S, Hafner M, Ascano M Jr, Tuschl T, Ohler U and Keene
JD: Integrative regulatory mapping indicates that the RNA-binding
protein HuR couples pre-mRNA processing and mRNA stability. Mol
Cell. 43:327–339. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Wang X, Li J, Bian X, Wu C, Hua J, Chang
S, Yu T, Li H, Li Y, Hu S, et al: CircURI1 interacts with hnRNPM to
inhibit metastasis by modulating alternative splicing in gastric
cancer. Proc Natl Acad Sci USA. 118:e20128811182021. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Yang J, Antin P, Berx G, Blanpain C,
Brabletz T, Bronner M, Campbell K, Cano A, Casanova J, Christofori
G, et al: Guidelines and definitions for research on
epithelial-mesenchymal transition. Nat Rev Mol Cell Biol.
21:341–352. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Denzler R, Agarwal V, Stefano J, Bartel DP
and Stoffel M: Assessing the ceRNA hypothesis with quantitative
measurements of miRNA and target abundance. Mol Cell. 54:766–776.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Chen XY, Yang YL, Yu Y, Chen ZY, Fan HN,
Zhang J and Zhu JS: CircUGGT2 downregulation by METTL14-dependent
m6A modification suppresses gastric cancer progression
and cisplatin resistance through interaction with miR-186-3p/MAP3K9
axis. Pharmacol Res. 204:1072062024. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Fang L, Lv J, Xuan Z, Li B, Li Z, He Z, Li
F, Xu J, Wang S, Xia Y, et al: Circular CPM promotes
chemoresistance of gastric cancer via activating PRKAA2-mediated
autophagy. Clin Transl Med. 12:e7082022. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Tang Z, Li J, Lu B, Zhang X, Yang L, Qi Y,
Jiang S, Wu Q, Wang Y, Cheng T, et al: CircBIRC6 facilitates the
malignant progression via miR-488/GRIN2D-mediated CAV1-autophagy
signal axis in gastric cancer. Pharmacol Res. 202:1071272024.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Ma S, Xu Y, Qin X, Tao M, Gu X, Shen L,
Chen Y, Zheng M, Qin S, Wu G and Ju S: RUNX1, FUS, and
ELAVL1-induced circPTPN22 promote gastric cancer cell
proliferation, migration, and invasion through miR-6788-5p/PAK1
axis-mediated autophagy. Cell Mol Biol Lett. 29:952024. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Yang J, Zhang X, Cao J, Xu P, Chen Z, Wang
S, Li B, Zhang L, Xie L, Fang L and Xu Z: Circular RNA UBE2Q2
promotes malignant progression of gastric cancer by regulating
signal transducer and activator of transcription 3-mediated
autophagy and glycolysis. Cell Death Dis. 12:9102021. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Sang H, Zhang W, Peng L, Wei S, Zhu X,
Huang K, Yang J, Chen M, Dang Y and Zhang G: Exosomal circRELL1
serves as a miR-637 sponge to modulate gastric cancer progression
via regulating autophagy activation. Cell Death Dis. 13:562022.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Liu Y, Cao J, Yang Q, Zhu L, Zhao W, Wang
X, Yao J, Zhou Y and Shao S: CircRNA_15430 reduced by Helicobacter
pylori infection and suppressed gastric cancer progression via
miR-382-5p/ZCCHC14 axis. Biol Direct. 18:512023. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Chen QY, Xu KX, Huang XB, Fan DH, Chen YJ,
Li YF, Huang Q, Liu ZY, Zheng HL, Huang ZN, et al: Circ-0075305
hinders gastric cancer stem cells by indirectly disrupting
TCF4-β-catenin complex and downregulation of SOX9. Commun Biol.
7:5452024. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Cai J, Chen Z, Wang J, Wang J, Chen X,
Liang L, Huang M, Zhang Z and Zuo X: circHECTD1 facilitates
glutaminolysis to promote gastric cancer progression by targeting
miR-1256 and activating β-catenin/c-Myc signaling. Cell Death Dis.
10:5762019. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Xia Y, Lv J, Jiang T, Li B, Li Y, He Z,
Xuan Z, Sun G, Wang S, Li Z, et al: CircFAM73A promotes the cancer
stem cell-like properties of gastric cancer through the
miR-490-3p/HMGA2 positive feedback loop and HNRNPK-mediated
β-catenin stabilization. J Exp Clin Cancer Res. 40:1032021.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Cao J, Zhang X, Xu P, Wang H, Wang S,
Zhang L, Li Z, Xie L, Sun G, Xia Y, et al: Circular RNA circLMO7
acts as a microRNA-30a-3p sponge to promote gastric cancer
progression via the WNT2/β-catenin pathway. J Exp Clin Cancer Res.
40:62021. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Guo X, Dai X, Liu J, Cheng A, Qin C and
Wang Z: Circular RNA circREPS2 acts as a sponge of miR-558 to
suppress gastric cancer progression by regulating RUNX3/β-catenin
signaling. Mol Ther Nucleic Acids. 21:577–591. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Zhou P, Qu H, Shi K, Chen X, Zhuang Z,
Wang N, Zhang Q, Liu Z, Wang L, Deng K, et al: ATF4-mediated
circTDRD3 promotes gastric cancer cell proliferation and metastasis
by regulating the miR-891b/ITGA2 axis and AKT signaling pathway.
Gastric Cancer. 26:565–579. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Peng L, Sang H, Wei S, Li Y, Jin D, Zhu X,
Li X, Dang Y and Zhang G: circCUL2 regulates gastric cancer
malignant transformation and cisplatin resistance by modulating
autophagy activation via miR-142-3p/ROCK2. Mol Cancer. 19:1562020.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Fei Y, Cao D, Li Y, Wang Z, Dong R, Zhu M,
Gao P, Wang X, Cai J and Zuo X: Circ_0008315 promotes tumorigenesis
and cisplatin resistance and acts as a nanotherapeutic target in
gastric cancer. J Nanobiotechnol. 22:5192024. View Article : Google Scholar
|
|
78
|
Huang X, Li Z, Zhang Q, Wang W, Li B, Wang
L, Xu Z, Zeng A, Zhang X, Zhang X, et al: Circular RNA AKT3
upregulates PIK3R1 to enhance cisplatin resistance in gastric
cancer via miR-198 suppression. Mol Cancer. 18:712019. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Deng G, Mou T, He J, Chen D, Lv D, Liu H,
Yu J, Wang S and Li G: Circular RNA circRHOBTB3 acts as a sponge
for miR-654-3p inhibiting gastric cancer growth. J Exp Clin Cancer
Res. 39:12020. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Zhang Y, Feng Z, Xu Y, Jiang S, Zhang Q,
Zhang Z, Wang K, Li X, Xu L, Yuan M, et al: Novel roles of LSECtin
in gastric cancer cell adhesion, migration, invasion, and lymphatic
metastasis. Cell Death Dis. 13:5932022. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Miao Z, Li J, Wang Y, Shi M, Gu X, Zhang
X, Wei F, Tang X, Zheng L and Xing Y: Hsa_circ_0136666 stimulates
gastric cancer progression and tumor immune escape by regulating
the miR-375/PRKDC Axis and PD-L1 phosphorylation. Mol Cancer.
22:2052023. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Song H, Xu Y, Xu T, Fan R, Jiang T, Cao M,
Shi L and Song J: CircPIP5K1A activates KRT80 and PI3K/AKT pathway
to promote gastric cancer development through sponging miR-671-5p.
Biomed Pharmacother. 126:1099412020. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Ma C, Wang X, Yang F, Zang Y, Liu J, Wang
X, Xu X, Li W, Jia J and Liu Z: Circular RNA hsa_circ_0004872
inhibits gastric cancer progression via the miR-224/Smad4/ADAR1
successive regulatory circuit. Mol Cancer. 19:1572020. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Xie M, Yu T, Jing X, Ma L, Fan Y, Yang F,
Ma P, Jiang H, Wu X, Shu Y and Xu T: Exosomal circSHKBP1 promotes
gastric cancer progression via regulating the miR-582-3p/HUR/VEGF
axis and suppressing HSP90 degradation. Mol Cancer. 19:1122020.
View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Xia Y, Jiang T, Li Y, Gu C, Lv J, Lu C, Xu
P, Fang L, Chen Z, Liu H, et al: circVAPA-rich small extracellular
vesicles derived from gastric cancer promote neural invasion by
inhibiting SLIT2 expression in neuronal cells. Cancer Lett.
592:2169262024. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Zhang Y, Wang X, Liu W, Lei T, Qiao T,
Feng W and Song W: CircGLIS3 promotes gastric cancer progression by
regulating the miR-1343-3p/PGK1 pathway and inhibiting vimentin
phosphorylation. J Transl Med. 22:2512024. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Xu P, Xu X, Wu X, Zhang L, Meng L, Chen Z,
Han W, Yao J and Xu A: CircTMC5 promotes gastric cancer progression
and metastasis by targeting miR-361-3p/RABL6. Gastric Cancer.
25:64–82. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Fan HN, Chen ZY, Chen XY, Chen M, Yi YC,
Zhu JS and Zhang J: METTL14-mediated m6A modification of
circORC5 suppresses gastric cancer progression by regulating
miR-30c-2-3p/AKT1S1 axis. Mol Cancer. 21:512022. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Du W, Li D, Guo X, Li P, Li X, Tong S,
Tong J, Kuang L and Liang D: Circ-PRMT5 promotes gastric cancer
progression by sponging miR-145 and miR-1304 to upregulate MYC.
Artif Cells Nanomed Biotechnol. 47:4120–4130. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Barrett T, Wilhite SE, Ledoux P,
Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH,
Sherman PM, Holko M, et al: NCBI GEO: Archive for functional
genomics data sets-update. Nucleic Acids Res. 41:D991–D995. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Dong Z, Liu Z, Liang M, Pan J, Lin M, Lin
H, Luo Y, Zhou X and Yao W: Identification of circRNA-miRNA-mRNA
networks contributes to explore underlying pathogenesis and therapy
strategy of gastric cancer. J Transl Med. 19:2262021. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Panda AC, Dudekula DB, Abdelmohsen K and
Gorospe M: Analysis of circular RNAs using the web tool
circinteractome. Methods Mol Biol. 1724:43–56. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Liu M, Wang Q, Shen J, Yang BB and Ding X:
Circbank: A comprehensive database for circRNA with standard
nomenclature. RNA Biol. 16:899–905. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Sticht C, De La Torre C, Parveen A and
Gretz N: miRWalk: An online resource for prediction of microRNA
binding sites. PLoS One. 13:e02062392018. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Lavenniah A, Luu TDA, Li YP, Lim TB, Jiang
J, Ackers-Johnson M and Foo RSY: Engineered circular RNA sponges
act as miRNA inhibitors to attenuate pressure overload-induced
cardiac hypertrophy. Mol Ther. 28:1506–1517. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Liu X, Abraham JM, Cheng Y, Wang Z, Wang
Z, Zhang G, Ashktorab H, Smoot DT, Cole RN, Boronina TN, et al:
Synthetic circular RNA functions as a miR-21 sponge to suppress
gastric carcinoma cell proliferation. Mol Ther Nucleic Acids.
13:312–321. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Shen Y, Zhang N, Chai J, Wang T, Ma C, Han
L and Yang M: CircPDIA4 induces gastric cancer progression by
promoting ERK1/2 activation and enhancing biogenesis of oncogenic
circRNAs. Cancer Res. 83:538–552. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Wu X, Fang Y, Gu Y, Shen H, Xu Y, Xu T,
Shi R, Xu D, Zhang J, Leng K, et al: Fat mass and
obesity-associated protein (FTO) mediated m6A
modification of circFAM192A promoted gastric cancer proliferation
by suppressing SLC7A5 decay. Mol Biomed. 5:112024. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Zang X, Jiang J, Gu J, Chen Y, Wang M,
Zhang Y, Fu M, Shi H, Cai H, Qian H, et al: Circular RNA EIF4G3
suppresses gastric cancer progression through inhibition of
β-catenin by promoting δ-catenin ubiquitin degradation and
upregulating SIK1. Mol Cancer. 21:1412022. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Ma Q, Yang F, Huang B, Pan X, Li W, Yu T,
Wang X, Ran L, Qian K, Li H, et al: CircARID1A binds to IGF2BP3 in
gastric cancer and promotes cancer proliferation by forming a
circARID1A-IGF2BP3-SLC7A5 RNA-protein ternary complex. J Exp Clin
Cancer Res. 41:2512022. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Ding P, Wu H, Wu J, Li T, He J, Ju Y, Liu
Y, Li F, Deng H, Gu R, et al: N6-methyladenosine modified circPAK2
promotes lymph node metastasis via targeting IGF2BPs/VEGFA
signaling in gastric cancer. Oncogene. 43:2548–2563. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Yu T, Ran L, Zhao H, Yin P, Li W, Lin J,
Mao H, Cai D, Ma Q, Pan X, et al: Circular RNA circ-TNPO3
suppresses metastasis of GC by acting as a protein decoy for
IGF2BP3 to regulate the expression of MYC and SNAIL. Mol Ther
Nucleic Acids. 26:649–664. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Hwang HJ and Kim YK: Molecular mechanisms
of circular RNA translation. Exp Mol Med. 56:1272–1280. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Yang Y, Fan X, Mao M, Song X, Wu P, Zhang
Y, Jin Y, Yang Y, Chen LL, Wang Y, et al: Extensive translation of
circular RNAs driven by N6-methyladenosine. Cell Res.
27:626–641. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Li A, Chen YS, Ping XL, Yang X, Xiao W,
Yang Y, Sun HY, Zhu Q, Baidya P, Wang X, et al: Cytoplasmic
m6A reader YTHDF3 promotes mRNA translation. Cell Res.
27:444–447. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Shi H, Wang X, Lu Z, Zhao BS, Ma H, Hsu
PJ, Liu C and He C: YTHDF3 facilitates translation and decay of
N6-methyladenosine-modified RNA. Cell Res. 27:315–328.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Boehm V and Gehring NH: Exon junction
complexes: Supervising the gene expression assembly line. Trends
Genet. 32:724–735. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Chang J, Shin MK, Park J, Hwang HJ, Locker
N, Ahn J, Kim D, Baek D, Park Y, Lee Y, et al: An interaction
between eIF4A3 and eIF3g drives the internal initiation of
translation. Nucleic Acids Res. 51:10950–10969. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Jiang T, Xia Y, Lv J, Li B, Li Y, Wang S,
Xuan Z, Xie L, Qiu S, He Z, et al: A novel protein encoded by
circMAPK1 inhibits progression of gastric cancer by suppressing
activation of MAPK signaling. Mol Cancer. 20:662021. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Hu F, Peng Y, Chang S, Luo X, Yuan Y, Zhu
X, Xu Y, Du K, Chen Y, Deng S, et al: Vimentin binds to a novel
tumor suppressor protein, GSPT1-238aa, encoded by circGSPT1 with a
selective encoding priority to halt autophagy in gastric carcinoma.
Cancer Lett. 545:2158262022. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Ruivo CF, Adem B, Silva M and Melo SA: The
biology of cancer exosomes: Insights and new perspectives. Cancer
Res. 77:6480–6488. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Kalluri R and LeBleu VS: The biology,
function, and biomedical applications of exosomes. Science.
367:eaau69772020. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Tai YL, Chen KC, Hsieh JT and Shen TL:
Exosomes in cancer development and clinical applications. Cancer
Sci. 109:2364–2374. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Zhang C, Wei G, Zhu X, Chen X, Ma X, Hu P,
Liu W, Yang W, Ruan T, Zhang W, et al: Exosome-delivered circSTAU2
inhibits the progression of gastric cancer by targeting the
miR-589/CAPZA1 axis. Int J Nanomedicine. 18:127–142. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Wang L, Bo X, Yi X, Xiao X, Zheng Q, Ma L
and Li B: Exosome-transferred LINC01559 promotes the progression of
gastric cancer via PI3K/AKT signaling pathway. Cell Death Dis.
11:7232020. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Deng C, Huo M, Chu H, Zhuang X, Deng G, Li
W, Wei H, Zeng L, He Y, Liu H, et al: Exosome circATP8A1 induces
macrophage M2 polarization by regulating the miR-1-3p/STAT6 axis to
promote gastric cancer progression. Mol Cancer. 23:492024.
View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Schneider J and Schulze G: Comparison of
tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen
(CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis
of gastrointestinal cancer. Anticancer Res. 23:5089–5093.
2003.PubMed/NCBI
|
|
118
|
Carpelan Holmström M, Louhimo J, Stenman
UH, Alfthan H and Haglund C: CEA, CA 19-9 and CA 72-4 improve the
diagnostic accuracy in gastrointestinal cancers. Anticancer Res.
22:2311–2316. 2002.PubMed/NCBI
|
|
119
|
Li T, Shao Y, Fu L, Xie Y, Zhu L, Sun W,
Yu R, Xiao B and Guo J: Plasma circular RNA profiling of patients
with gastric cancer and their droplet digital RT-PCR detection. J
Mol Med (Berl). 96:85–96. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Roy S, Kanda M, Nomura S, Zhu Z, Toiyama
Y, Taketomi A, Goldenring J, Baba H, Kodera Y and Goel A:
Diagnostic efficacy of circular RNAs as noninvasive, liquid biopsy
biomarkers for early detection of gastric cancer. Mol Cancer.
21:422022. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Shao Y, Li J, Lu R, Li T, Yang Y, Xiao B
and Guo J: Global circular RNA expression profile of human gastric
cancer and its clinical significance. Cancer Med. 6:1173–1180.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Zhang Y, Li J, Yu J, Liu H, Shen Z, Ye G,
Mou T, Qi X and Li G: Circular RNAs signature predicts the early
recurrence of stage III gastric cancer after radical surgery.
Oncotarget. 8:22936–22943. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Xiao K, Li S, Ding J, Wang Z, Wang D, Cao
X, Zhang Y and Dong Z: Expression and clinical value of circRNAs in
serum extracellular vesicles for gastric cancer. Front Oncol.
12:9628312022. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Helleday T, Petermann E, Lundin C, Hodgson
B and Sharma RA: DNA repair pathways as targets for cancer therapy.
Nat Rev Cancer. 8:193–204. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Xue M, Li G, Fang X, Wang L, Jin Y and
Zhou Q: hsa_circ_0081143 promotes cisplatin resistance in gastric
cancer by targeting miR-646/CDK6 pathway. Cancer Cell Int.
19:252019. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Zhao J, Nie Y, Wang H and Lin Y: MiR-181a
suppresses autophagy and sensitizes gastric cancer cells to
cisplatin. Gene. 576:828–833. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Dong X, Wang Y, Zhou Y, Wen J, Wang S and
Shen L: Aquaporin 3 facilitates chemoresistance in gastric cancer
cells to cisplatin via autophagy. Cell Death Discov. 2:160872016.
View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Sun G, Li Z, He Z, Wang W, Wang S, Zhang
X, Cao J, Xu P, Wang H, Huang X, et al: Circular RNA MCTP2 inhibits
cisplatin resistance in gastric cancer by miR-99a-5p-mediated
induction of MTMR3 expression. J Exp Clin Cancer Res. 39:2462020.
View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y,
Liu W, Tong J, Liu Y, Xu R, et al: Randomized, double-blind,
placebo-controlled phase III trial of apatinib in patients with
chemotherapy-refractory advanced or metastatic adenocarcinoma of
the stomach or gastroesophageal junction. J Clin Oncol.
34:1448–1454. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Masuda K, Shoji H, Nagashima K, Yamamoto
S, Ishikawa M, Imazeki H, Aoki M, Miyamoto T, Hirano H, Honma Y, et
al: Correlation between immune-related adverse events and prognosis
in patients with gastric cancer treated with nivolumab. BMC Cancer.
19:9742019. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Aoki M, Shoji H, Nagashima K, Imazeki H,
Miyamoto T, Hirano H, Honma Y, Iwasa S, Okita N, Takashima A, et
al: Hyperprogressive disease during nivolumab or irinotecan
treatment in patients with advanced gastric cancer. ESMO Open.
4:e0004882019. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Sunakawa Y, Inoue E, Matoba R, Kawakami H,
Sato Y, Nakajima TE, Muro K, Ichikawa W and Fujii M: DELIVER
(JACCRO GC-08) trial: Discover novel host-related immune-biomarkers
for nivolumab in advanced gastric cancer. Future Oncol.
15:2441–2447. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Bang YJ, Kang YK, Catenacci DV, Muro K,
Fuchs CS, Geva R, Hara H, Golan T, Garrido M, Jalal SI, et al:
Pembrolizumab alone or in combination with chemotherapy as
first-line therapy for patients with advanced gastric or
gastroesophageal junction adenocarcinoma: Results from the phase II
nonrandomized KEYNOTE-059 study. Gastric Cancer. 22:828–837. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Bang YJ, Van Cutsem E, Fuchs CS, Ohtsu A,
Tabernero J, Ilson DH, Hyung WJ, Strong VE, Goetze TO, Yoshikawa T,
et al: KEYNOTE-585: Phase III study of perioperative chemotherapy
with or without pembrolizumab for gastric cancer. Future Oncol.
15:943–952. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Kulangara K, Zhang N, Corigliano E,
Guerrero L, Waldroup S, Jaiswal D, Ms MJ, Shah S, Hanks D, Wang J,
et al: Clinical utility of the combined positive score for
programmed death ligand-1 expression and the approval of
pembrolizumab for treatment of gastric cancer. Arch Pathol Lab Med.
143:330–337. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Roviello G, D'Angelo A, Generali D,
Pittacolo M, Ganzinelli M, Iezzi G, de Manzini N and Sobhani N:
Avelumab in gastric cancer. Immunotherapy. 11:759–768. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Chen DL, Sheng H, Zhang DS, Jin Y, Zhao
BT, Chen N, Song K and Xu RH: The circular RNA circDLG1 promotes
gastric cancer progression and anti-PD-1 resistance through the
regulation of CXCL12 by sponging miR-141-3p. Mol Cancer.
20:1662021. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Wang B, Liu W, Zhang M, Li Y, Tang H, Wang
Y, Song C, Song B and Tan B: Circ_0001947 encapsulated by small
extracellular vesicles promotes gastric cancer progression and
anti-PD-1 resistance by modulating CD8+ T cell
exhaustion. J Nanobiotechnology. 22:5632024. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Lin L, Li H, Shi D, Liu Z, Wei Y, Wang W,
Wu D, Li B and Guo Q: Depletion of C12orf48 inhibits gastric cancer
growth and metastasis via up-regulating Poly r(C)-binding protein
(PCBP) 1. BMC Cancer. 22:1232022. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Guo J and Jia R: Splicing factor
poly(rC)-binding protein 1 is a novel and distinctive tumor
suppressor. J Cell Physiol. 234:33–41. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Huang S, Luo K, Jiang L, Zhang XD, Lv YH
and Li RF: PCBP1 regulates the transcription and alternative
splicing of metastasis-related genes and pathways in hepatocellular
carcinoma. Sci Rep. 11:233562021. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Chen Y, Dou Z, Chen X, Zhao D, Che T, Su
W, Qu T, Zhang T, Xu C, Lei H, et al: Overexpression of splicing
factor poly(rC)-binding protein 1 elicits cycle arrest, apoptosis
induction, and p73 splicing in human cervical carcinoma cells. J
Cancer Res Clin Oncol. 148:3475–3484. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Zhou M, Dong J, Huang J, Ye W, Zheng Z,
Huang K, Pan Y, Cen J, Liang Y, Shu G, et al: Chitosan-gelatin-EGCG
nanoparticle-mediated lncRNA TMEM44-AS1 silencing to activate the
P53 signaling pathway for the synergistic reversal of 5-FU
resistance in gastric cancer. Adv Sci (Weinh). 9:e21050772022.
View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Abeyrathne ED, Lee HY and Ahn DU: Egg
white proteins and their potential use in food processing or as
nutraceutical and pharmaceutical agents-a review. Poult Sci.
92:3292–3299. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Dawidczyk CM, Kim C, Park JH, Russell LM,
Lee KH, Pomper MG and Searson PC: State-of-the-art in design rules
for drug delivery platforms: Lessons learned from FDA-approved
nanomedicines. J Control Release. 187:133–144. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Devulapally R, Foygel K, Sekar TV,
Willmann JK and Paulmurugan R: Gemcitabine and antisense-microRNA
co-encapsulated PLGA-PEG polymer nanoparticles for hepatocellular
carcinoma therapy. ACS Appl Mater Interfaces. 8:33412–33422. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Li Y, Zheng Q, Bao C, Li S, Guo W, Zhao J,
Chen D, Gu J, He X and Huang S: Circular RNA is enriched and stable
in exosomes: A promising biomarker for cancer diagnosis. Cell Res.
25:981–984. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Tian L, Gao Y, Zi L, Zhe R and Yang J:
Dual Cas12a and multiplex crRNA CRISPR strategy ultrasensitive
detection novel circRNA biomarker for the diagnosis of ovarian
cancer. BMC Cancer. 25:6952025. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
He AT, Liu J, Li F and Yang BB: Targeting
circular RNAs as a therapeutic approach: Current strategies and
challenges. Signal Transduct Target Ther. 6:1852021. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Qi L, Pan Y, Tang M and Chen X:
Circulating cell-free circRNA panel predicted tumorigenesis and
development of colorectal cancer. J Clin Lab Anal. 36:e244312022.
View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Xian J, Su W, Liu L, Rao B, Lin M, Feng Y,
Qiu F, Chen J, Zhou Q, Zhao Z, et al: Identification of three
circular RNA cargoes in serum exosomes as diagnostic biomarkers of
non-small-cell lung cancer in the Chinese population. J Mol Diagn.
22:1096–1108. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Digby B, Finn S and Ó Broin P:
Computational approaches and challenges in the analysis of circRNA
data. BMC genomics. 25:5272024. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Wang F, Cai G, Wang Y, Zhuang Q, Cai Z, Li
Y, Gao S, Li F, Zhang C, Zhao B and Liu X: Circular RNA-based
neoantigen vaccine for hepatocellular carcinoma immunotherapy.
MedComm (2020). 5:e6672024. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Qu L, Yi Z, Shen Y, Lin L, Chen F, Xu Y,
Wu Z, Tang H, Zhang X, Tian F, et al: Circular RNA vaccines against
SARS-CoV-2 and emerging variants. Cell. 185:1728–1744.e16. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Li H, Peng K, Yang K, Ma W, Qi S, Yu X, He
J, Lin X and Yu G: Circular RNA cancer vaccines drive immunity in
hard-to-treat malignancies. Theranostics. 12:6422–6436. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Ren Y, Manoharan T, Liu B, Cheng CZM, En
Siew B, Cheong WK, Lee KY, Tan IJ, Lieske B, Tan KK and Chia G:
Circular RNA as a source of neoantigens for cancer vaccines. J
Immunother Cancer. 12:e0084022024. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Hu Q, Zhao H, Zhou K, Hua X and Zhang X:
Scarless circular mRNA-based CAR-T cell therapy elicits superior
anti-tumor efficacy. bioRxiv. 2024.2008. 2005.606578. 2024.
|
|
158
|
Kulcheski FR, Christoff AP and Margis R:
Circular RNAs are miRNA sponges and can be used as a new class of
biomarker. J Biotechnol. 238:42–51. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Alsaab HO, Alharbi FD, Alhibs AS, Alanazi
NB, Alshehri BY, Saleh MA, Alshehri FS, Algarni MA, Almugaiteeb T,
Uddin MN and Alzhrani RM: PLGA-based nanomedicine: History of
advancement and development in clinical applications of multiple
diseases. Pharmaceutics. 14:27282022. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Danhier F, Ansorena E, Silva JM, Coco R,
Le Breton A and Préat V: PLGA-based nanoparticles: An overview of
biomedical applications. J Control Release. 161:505–522. 2012.
View Article : Google Scholar : PubMed/NCBI
|
